Re: SRDX, NVS, AGN
>would you agree this announcement seems to make the idea of a Novartis-SRDX relationship on the SRI less likely?<
Perhaps—but the larger issue is that NVS does not (to my knowledge) have any early-stage drug candidates in ophthalmology to marry with SRDX’s SRI platform.
The NVS unit that will be co-promoting BOL’s Retisert device is the unit formerly known as CibaVision, which sells contact lenses and solutions and operates somewhat independently from the parent company.
Incidentally, AGN spent half an hour in their R&D webcast earlier this month on Posurdex and their other development programs for retinal diseases. I was not impressed—AGN seems to have lost ground in this area compared to SRDX and other competitors.
Market Data 
Markets 
AI
